Serum LPS and CD163 Biomarkers Confirming the Role of Gut Dysbiosis in Overweight Patients with NASH
Mona A Hegazy,1 Sherif M Mogawer,1 Alshaimaa Rezk L R Alnaggar,1 Olfat A Ghoniem,2 Rasha M Abdel Samie1 1Internal Medicine Department, Kasr Alainy Hospital, Faculty of Medicine, Cairo University, Cairo, Egypt; 2Internal Medicine, Ministry of Health, Cairo, EgyptCorrespondence: Mona A Hegazy Tel +201...
Guardado en:
Autores principales: | Hegazy MA, Mogawer SM, Alnaggar ARLR, Ghoniem OA, Abdel Samie RM |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/53ceea8353844bc68dbcb727c3ef0c6f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Novel Application of the Traditional Lipid Ratios as Strong Risk Predictors of NASH
por: Hegazy M, et al.
Publicado: (2020) -
The Effect of Visfatin on Inflammatory Reaction in Uterus of LPS-Induced Rats
por: Yang,Zhi, et al.
Publicado: (2015) -
Current and Potential Therapies Targeting Inflammation in NASH
por: Somaya Albhaisi, et al.
Publicado: (2021) -
Clinical utility of urinary soluble CD163 in evaluation of lupus nephritis patients
por: Nada M. Gamal, et al.
Publicado: (2022) -
Effect of Visfatin on the Structure and Immune Levels in the Small Intestine of LPS-Induced Rats
por: Zhou,Ying, et al.
Publicado: (2015)